Document:

exv10w1

Exhibit 10.1

Description of Bonus Plan

The Compensation Committee (the “Committee”) of the Board of Directors of Peoples Financial
Corporation (the “Company”) awards bonuses to the Company’s executive officers based upon
pre-determined performance objectives. The executive officers are eligible to receive a bonus which
is based on the financial performance of the Company. The specific formula and pre-determined goals
were established by the Committee using the Company’s return on average assets (“ROA”). The bonus
calculation, which is approved by the Committee, allows the executive officer to earn up to a
maximum percentage of their salary on established ROA targets. The targets and bonus calculations
as a percentage of salary and targets are:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Base	 	 	Base + 1	 	 	Base + 2	 	 	Base + 3	 	 	Maximum	 
	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ROA Target
	 	 	.670	%	 	 	.800	%	 	 	.925	%	 	 	1.050	%	 	 	1.175	%
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Chief Executive Officer
	 	 	15.000	%	 	 	18.750	%	 	 	22.500	%	 	 	26.250	%	 	 	30.000	%
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Executive Vice President
	 	 	12.500	%	 	 	15.630	%	 	 	18.750	%	 	 	21.880	%	 	 	25.000	%
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	All Other Named
Executive Officers
	 	 	10.000	%	 	 	12.500	%	 	 	15.000	%	 	 	17.500	%	 	 	20.000	%exv10w59

Exhibit 10.59

AMENDMENT NO. 2 TO

AMERICAN PHYSICIANS ASSURANCE CORPORATION

EXECUTIVE EMPLOYMENT AGREEMENT

     THIS AMENDMENT No. 2, dated June 22, 2010, amends the Employment Agreement between American
Physicians Assurance Company (the “Company”) and [ ] (the “Executive”) dated as of [ ], 2005, as
amended (the “Employment Agreement”).

     WHEREAS, the Board and the Executive desire to clarify certain provisions of the Employment
Agreement;

     WHEREAS, Section 17 of the Employment Agreement permits the parties to amend the Employment
Agreement by a written agreement that specifically references the Employment Agreement and the
parties hereto desire and intend for this Amendment No. 2 to fulfill the requirements of Section
17; and

     WHEREAS, the Compensation Committee of the Board has determined that the terms of this
Amendment No. 2 are in ACAP’s and the Company’s best interests;

     NOW THEREFORE, in consideration of the foregoing and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged by the parties, the Employment
Agreement is amended as set forth below.

     1. The introductory sentence in Section 7(d) is hereby amended and restated in its entirety to
read as follows:

     In the event the Executive’s employment is terminated under
Section 6(d) or 6(e), the Company shall pay or provide to the
Executive or his personal representative, subject to the Executive
or the personal representative signing and delivering to the Company
a release and separation agreement reasonably acceptable to the
Company, which shall become final and binding no later than 30 days
following the Date of Termination:

     3. Except as specifically modified herein, the remaining provisions of the Employment
Agreement remain in full force and effect.

     4. The term “Employment Agreement” as used in the Employment Agreement shall be deemed to
refer to the Employment Agreement as amended through the date hereof (including without limitation
by this Amendment No. 2).

     5. This Amendment may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to be duly executed as
of the day and year first above written.

 

 

EXECUTIVE

                                         (signature)

[       ]                              (name)

AMERICAN PHYSICIANS ASSURANCE CORPORATION

AMERICAN PHYSICIANS CAPITAL, INC.

By:                                         

Name: [       ]

Title: [       ]exv10w1

Exhibit 10.1

Chindex International, Inc.

Executive Management Incentive Program (EMIP)

For the Fiscal Year Ending March 31, 2011

Recognizing that the principal reason for the existence of a corporate entity is to increase
shareholder wealth and that this generally translates into the maximization of profits over time
and is or should be the primary goal of a publicly held corporation, Chindex International, Inc.
(Parent Company) has adopted this Executive Management Incentive Program (EMIP) to help align
remunerative management incentives with the interests of the company’s shareholding public. This
EMIP is adopted pursuant to the Chindex International, Inc. 2007 Stock Incentive Plan.

Enrollment

The three executive officers of the Parent Company are automatically enrolled in and are
beneficiaries of this EMIP. They are the Chief Executive Officer (CEO), the Chief Financial
Officer (CFO) and the Executive Vice President (EVP) in charge of the Medical Products Division
(MPD).

Weighting

There are two parts to the plan based on the Annual Objective Performance Criteria (AOPC). Sixty
percent (60%) of the incentive payout is based on the achievement of Financial Objectives and forty
percent (40%) of the incentive payout is based on the achievement of Non-financial Objectives, as
described below.

The Compensation Committee may in its discretion determine to pay a discretionary bonus to one or
more executive officers in addition to amounts earned based on the Annual Objective Performance
Criteria, as described below.

Annual Objective Performance Criteria

Financial Objectives: The metric of annual performance related to the Financial Objectives is
weighted equally between two components: (1) growth in revenue over the prior year, and (2) growth
in operating income, as adjusted, over the prior year.

Non-financial Objectives: The metric of annual performance related to Non-financial Objectives is
assessed by the Compensation Committee relative to fulfillment of various non-financial objectives
such as developmental and transformational projects, human resources and successor development and
other objectives agreed with the Committee at the beginning of or during the relevant fiscal year.

Incentive payments to any executive enrolled in the EMIP with respect to Annual Objective
Performance Criteria will not exceed 55% of base salary and shall be calculated in accordance with
the following table. The portion of incentive payments related to Financial Objectives for the CEO
and CFO shall be based on the Financial Objectives of the Parent Company. The portion of incentive
payments related to Financial Objectives for the EVP of MPD shall be based 50% on the Financial
Objectives of MPD and 50% on the Financial Objectives of the Parent Company.

 

 

2

	 	 	 	 	 
	 	 	Cash Bonus as
	 	 	a % of Base
	Annual Objective Performance Criteria	 	Salary*
	 
	 	 	 	 
	Financial Objectives
	 	 	 	 
	Revenue Growth
	 	 	 	 
	Below growth range
	 	 	0	%
	Within growth range
	 	 	15	%
	Exceeding growth range
	 	 	17.5	%
	 
	 	 	 	 
	Operating Income Growth
	 	 	 	 
	Below growth range
	 	 	0	%
	Within growth range
	 	 	15	%
	Exceeding growth range
	 	 	17.5	%
	 
	 	 	 	 
	Non-financial Objectives
	 	 	 	 
	Failure to complete objectives
	 	 	0	%
	Partial completion of objectives
	 	 	10	%
	Substantial completion of objectives
	 	 	20	%

With respect to the Financial Objectives, the growth range referred to in the above table is
as follows:

	 	 	 	 	 	 	 	 	 
	 	 	Parent Company	 	MPD
	Revenue Growth
	 	 	17-21	%	 	 	13-17	%
	Operating Income Growth
	 	 	21-31	%	 	$	1.7 -$2.2m	 

Compensation Committee Determination

The determination of whether, and the extent to which, the Annual Objective Performance Criteria
have been satisfied shall be made in the sole judgment of the Compensation Committee based on
year-end financial information provided by management, which determination shall be made within 120
days after the fiscal year-end. The Committee, in its sole discretion, shall have the right to
reduce the amount payable under the EMIP if it determines that such reduction is appropriate to
reflect adjustments on account of non-recurring events or other unanticipated circumstances.

Discretionary Bonus

In addition to the payouts based on the Annual Objective Performance Criteria shown above, the
Compensation Committee may, in its sole discretion, award a discretionary cash bonus not to exceed
50% of base salary to one or more of the executive officers to reward extraordinary efforts or
achievements during the relevant fiscal year.

Payment of Award

Payments under this EMIP shall be made as soon as practical following the close of the Company’s
fiscal year and in any event within 180 days following such close. Entitlement to any payments
under this EMIP shall be contingent on the participant being employed by the Company on the date of
Compensation Committee determination of the amount of the payment, unless otherwise provided in the
executive’s Employment Agreement.

 

			
	*	 	Total Actual Base Salary received during Fiscal Year 2011exv10w4

Exhibit 10.4

DEG *
Postfach 10 09 61 * 50449 Köln

Chindex China Healthcare

Finance LLC

Lawrence Pemble

Chindex International, Inc.

Bethesda,

4340 East West Highway, Suite 1100

20814 MARYLAND

VEREINIGTE STAATEN VON AMERIKA

By Facsimile:+1 301 215 7719

	 	 	 

	Thomasine Calow
	Our ref.:

	 	VD / CAL
	 
	 	 
	Extension:

	 	0221 4986 1798 
	Fax:

	 	0221 4986 1198 
	E-mail:

	 	CAL@deginvest.de
	Date:

	 	06.07.2010 

Chindex
China Healthcare Finance LLC – Loan Agreement dated 08.01.2008
– Request for
extension of first Disbursement

Dear Mr. Pemble,

1.
Reference is made to the Loan Agreement dated February 8, 2008 (the “Loan Agreement”), by and
among Chindex China Healthcare Finance LLC (the “Company”) and DEG. Capitalized terms are not
defined in this letter and shall have the same meaning accorded to them in the Loan Agreement.

2. Contingent on IFC’s corresponding extension of the Disbursement deadline becoming effective,
the parties hereby agree to extend the deadline for first Disbursement referred to in Section
2.12.(a)(i) of the Loan Agreement until October 1, 2010 and to amend the Loan Agreement as set
forth below.

3. Section 2.12.(a)(i) is hereby amended as follows:

2.12.(a)(i) If the first Disbursement to such Onshore Borrower has not been made by October 1,
2010, or such other later date as DEG and Chindex agree;

For the avoidance of doubt this amendment shall be limited as specified and shall not constitute a
novation or modification of any of the other provisions of the Loan Agreement which shall continue
in full force and effect except as provided in this Amendment and this Amendment shall constitute
an integral and complementary part of the Loan Agreement for all legal purposes and effects.

4. The above extension of Disbursement shall not be understood as an acceptance by DEG of the
changes regarding the projects as communicated to date. The terms and conditions of the loan
agreements to be entered into with the Onshore Borrowers are subject to change depending on the
outcome of further analysis.

	 	 	 

		 	DEG – Deutsche Investitions- und Entwicklungsgesellschaft mbH *
Kämmergasse 22 * 50676 Köln  * www.deginvest.de Telefon:
0221 4986-0 * Telefax: 0221 4986-1290 * Vorsitzende des
Aufsichtsrates: Gudrun Kopp * Geschäftsführung: Dr. Michael
Bornmann, Philipp Kreutz, Bruno Wenn (Sprecher) *
Sitz der Gesellschaft: Köln * Amtsgericht Köln HRB 1005
Bankverbindung: Deutsche Bundesbank, Filiale Köln, BLZ: 370 000 00,
Konto: 370 085 35 * USt-IdNr.: DE 123 489 824

 

 

- 2 -

	5.	 	Please acknowledge your agreement and acceptance of the foregoing by countersigning
the enclosed duplicates of this Letter in the space provided below and returning one executed original to DEG

	 	 	 

	Yours sincerely,
	 
	 	 
	DEG — Deutsche Investitions- und
	Entwicklungsgesellschaft mbH
	 
	 	 
	

	 	
	Josef Boven

	 	Thomasine Calow

	 	 	 	 	 

	Amendment accepted and agreed for on behalf of the Company:
	Chindex China Healthcare Finance, LLC
	 
	 	 	 	 
	By:

	 	/s/ Lawrence Pemble	 	 
	Name:

	 	Lawrence Pemble	 	 
	Title:

	 	CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]